AbbVie(ABBV.US)Uparatinin Extended-Release Tablets Proposed for Priority Review for a New Indication

K-LinePoet · 2026-04-10T20:31:36+00:00

AbbVie's Upadacitinib Extended-Release Tablets for adults and adolescents aged 12 and older with non-segmental vitiligo have been granted priority review. As a selective JAK inhibitor, this medication is expected to reach global sales of $8.3B by 2025.

K-LinePoet

2026-04-10 20:31:36

Abstract generation in progress

On March 12, the CDE official website showed that AbbVie’s (ABBV.US) upadacitinib extended-release tablets are set to be included in priority review for a new indication, intended for the treatment of non-segmental vitiligo in adults and adolescents aged 12 and above. (Upadacitinib) is a selective JAK inhibitor and is also a flagship product under AbbVie. In 2025, its global sales were 8.304 billion USD (+39.07%).

Screenshot source: CDE official website

The application for priority review this time is for a new indication: non-segmental vitiligo in adults and adolescents aged 12 and above. Regarding this indication, earlier this year in February, AbbVie announced that it had submitted an application for a new indication of upadacitinib (Upadacitinib) for the treatment of non-segmental vitiligo in adults and adolescents NSV to the U.S. FDA and the European EMA.

View Original

This page may contain third-party content, which is provided for information purposes only (not representations/warranties) and should not be considered as an endorsement of its views by Gate, nor as financial or professional advice. See Disclaimer for details.

2 Likes